N.C. Gen. Stat. § 90-325.3
No liability to heirs for outstanding debt related to use of investigational drugs, biological products, or devices
Redline — June 1, 2021 → current.View current text →
Current — April 1, 2022
As of June 1, 2021
If an eligible patient dies while being treated with an investigational drug, biological product, or device, the eligible patient's heirs are not liable for any outstanding debt related to the treatment, including any costs attributed to lack of insurance coverage for the treatment.
If an eligible patient dies while being treated with an investigational drug, biological product, or device, the eligible patient’s heirs are not liable for any outstanding debt related to the treatment, including any costs attributed to lack of insurance coverage for the treatment.
History
(2015-137, s. 1.)
Official source: North Carolina General Assembly. Reproduced from public-domain North Carolina statutes; confirm against the official source for the current text. Not legal advice.